Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1062978

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1062978

Monoclonal Antibodies (MAbS) Global Market Report 2022

Published: Pre-Order
PAGES: 300 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

“Monoclonal Antibodies (MAbS) Global Market Report 2022” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global monoclonal antibodies (mabs) market as it emerges from the Covid 19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Monoclonal Antibodies (MAbS) Market Global Report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The Market Characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the Covid 19 virus and forecasting its recovery.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of Covid 19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Source: Murine; Chimeric; Humanized; Human

2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAbs); Neuropharmacological; Cardiovascular And Cerebrovascular; Others

3) By End Users: Hospitals; Private Clinics; Research Institute

Companies Mentioned: Johnson & Johnson; Merck; AbbVie; Amgen; Glaxosmithkline plc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: h1200

Table of Contents

1. Executive Summary

2. Monoclonal Antibodies (MAbS) Market Characteristics

3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

4. Impact Of COVID-19 On Monoclonal Antibodies (MAbS)

5. Monoclonal Antibodies (MAbS) Market Size And Growth

  • 5.1. Global Monoclonal Antibodies (MAbS) Historic Market, 2016-2021, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Monoclonal Antibodies (MAbS) Forecast Market, 2021-2026F, 2031F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Monoclonal Antibodies (MAbS) Market Segmentation

  • 6.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Murine
  • Chimeric
  • Humanized
  • Human
  • 6.2. Global Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Anti-Cancer
  • Immunological
  • Anti-Infective Monoclonal Antibodies (Mabs)
  • Neuropharmacological
  • Cardiovascular And Cerebrovascular
  • Others
  • 6.3. Global Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals
  • Private Clinics
  • Research Institute

7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis

  • 7.1. Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 7.2. Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Monoclonal Antibodies (MAbS) Market

  • 8.1. Asia-Pacific Monoclonal Antibodies (MAbS) Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 8.3. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 8.4. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Monoclonal Antibodies (MAbS) Market

  • 9.1. China Monoclonal Antibodies (MAbS) Market Overview
  • 9.2. China Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
  • 9.3. China Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
  • 9.4. China Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Monoclonal Antibodies (MAbS) Market

  • 10.1. India Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 10.2. India Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 10.3. India Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Monoclonal Antibodies (MAbS) Market

  • 11.1. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 11.2. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 11.3. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Monoclonal Antibodies (MAbS) Market

  • 12.1. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 12.2. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 12.3. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Monoclonal Antibodies (MAbS) Market

  • 13.1. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 13.2. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 13.3. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Monoclonal Antibodies (MAbS) Market

  • 14.1. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 14.2. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 14.3. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Monoclonal Antibodies (MAbS) Market

  • 15.1. Western Europe Monoclonal Antibodies (MAbS) Market Overview
  • 15.2. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 15.3. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 15.4. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Monoclonal Antibodies (MAbS) Market

  • 16.1. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 16.2. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 16.3. UK Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Monoclonal Antibodies (MAbS) Market

  • 17.1. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 17.2. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 17.3. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Monoclonal Antibodies (MAbS) Market

  • 18.5. France Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 18.6. France Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 18.7. France Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Monoclonal Antibodies (MAbS) Market

  • 19.1. Eastern Europe Monoclonal Antibodies (MAbS) Market Overview
  • 19.2. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 19.3. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 19.4. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Monoclonal Antibodies (MAbS) Market

  • 20.1. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 20.2. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 20.3. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Monoclonal Antibodies (MAbS) Market

  • 21.1. North America Monoclonal Antibodies (MAbS) Market Overview
  • 21.2. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 21.3. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 21.4. North America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Monoclonal Antibodies (MAbS) Market

  • 22.1. USA Monoclonal Antibodies (MAbS) Market Overview
  • 22.2. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 22.3. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 22.4. USA Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Monoclonal Antibodies (MAbS) Market

  • 23.1. South America Monoclonal Antibodies (MAbS) Market Overview
  • 23.2. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 23.3. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 23.4. South America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Monoclonal Antibodies (MAbS) Market

  • 24.1. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 24.2. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 24.3. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Monoclonal Antibodies (MAbS) Market

  • 25.1. Middle East Monoclonal Antibodies (MAbS) Market Overview
  • 25.2. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 25.3. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 25.4. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Monoclonal Antibodies (MAbS) Market

  • 26.1. Africa Monoclonal Antibodies (MAbS) Market Overview
  • 26.2. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 26.3. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • 26.4. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles

  • 27.1. Monoclonal Antibodies (MAbS) Market Competitive Landscape
  • 27.2. Monoclonal Antibodies (MAbS) Market Company Profiles
    • 27.2.1. Johnson & Johnson
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Merck
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. AbbVie
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Amgen
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Glaxosmithkline plc
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Monoclonal Antibodies (MAbS) Pipeline Analysis

29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Research Inquiries
  • 31.4. The Business Research Company
  • 31.5. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!